News round-up by DDW’s Reece Armstrong for 8-12 August
New insights into melanoma, a company transition into life sciences and a Lyme disease vaccine are some of the stories in this week’s news round-up.
Pfizer launches Phase III trial for Lyme disease vaccine
Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva.
Cerevance teams up with Merck (MSD) on Alzheimer’s project
Drug discovery and development company Cerevance has announced a multi-year strategic research collaboration with Merck (MSD), focused on identifying novel targets for Alzheimer’s disease.
Oxeia Biopharmaceuticals encouraged by concussion treatment
Clinical stage biotech company Oxeia Biopharmaceuticals has announced interim results from a Phase II trial investigating its treatment for concussion.
PerkinElmer focuses on life sciences in $2.45bn deal
Life sciences company PerkinElmer will divest its Applied, Food and Enterprise Services to the private equity firm New Mountain Capital in a potential deal worth $2.45 billion.
Scientists discover how melanoma invades new tissue
Scientists have discovered how melanoma skin cancer cells invade new tissues in research they hope might lead to new treatments.
